Podcasts about Tolerability

In his weekly clinical update, Dr. Griffin and Vincent Racaniello discuss in shock how RFK is breaking his promise of not altering vaccine policies by appointing new members of the ACIP, next ACIP meeting on guidelines for the COVID and RSV vaccines, circulation of “human insect viruses” including West Nile virus, and an outbreak of mpox on a cruise ship, and the ongoing measles outbreak before Dr. Griffin reviews recent statistics on RSV, influenza and SARS-CoV-2 infections the Wasterwater Scan dashboard, how to reduce the use of antibiotics for RSV and influenza infections in children, approval of the moderna RSV mRNA vaccine, whether or not the NB.1.8.1 should be included in the fall 2025 vaccines, immunization recommendations for COVID-19 vaccines, where to find PEMGARDA, provides information for Columbia University Irving Medical Center's long COVID treatment center, where to go for answers to your long COVID questions, contacting your federal government representative to stop the assault on science and biomedical research, and a shout out for the special episode of TWiV with David Tuller on long COVID and ME/CFS. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode RFK Jr. is sabotaging the vaccine program. Here's how to stop him (Washington Post) Innovaciones Alumbra (Alumbra Innovaciones) John T Walton (Wikiepedia) Walmart (Wikipedia) Sam Walton (Wikipedia) Condé Nast (Wikipedia) Christy Walton (Wikipedia) Vaccine Integrity Project ( CIDRAP) CIDRAP launches Vaccine Integrity Project (Twin Cities: University of Minnesota) Next ACIP meeting (CDC: ACIP) June meeting: MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)(CDC: ACIP agenda) West Nile Virus and Other Nationally Notifiable Arboviral Diseases — United States, 2023 (CDC: MMWR) Clade II Mpox Infections Among Cruise Ship Passengers and Crew Members — United States, 2024 (CDC: MMWR) H5 bird flu: current situation (CDC: Avian Influenza) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola) Measles vaccine recommendations from NYP (jpg) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Pediatric antibiotic use associated with respiratory syncytial virus and influenza in the United States, 2008-2018 (JID) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Novel Drug Approvals for 2025 (FDA) Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL) (LANCET: Infectious Diseases) Safety, Tolerability, and Immunogenicity ofmRNA-1345 in Adults at Increased Risk for RSV Disease Aged 18 to 59 Years (CID) Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease (moderna) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) Spatiotemporal Association of Coronavirus Disease 2019 Cases and Deaths With Exposure to Wildfire Particulate Matter in 2020 (OFID) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Next ACIP meeting (CDC: ACIP) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (biRxiV) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Implementation of an online drug-drug interaction screener for the STRIVE ensitrelvir trial for COVID-19 (OFID) Drug interaction checker (University of Liverpool) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Steroids,dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Long COVID and ME/CFS with David Tuller (microbeTV) Reaching out to US house representative Letters read on TWiV 1228 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Drs. Brander and Cohen discuss an ongoing debate in the management of CLL about BTK and BCL2 inhibitor combinations in the frontline treatment of CLL. Is it better to combine BTK and BCL2 inhibitors, or to start with one or the other as monotherapy?

In today's VETgirl online veterinary continuing education podcast, we review the American Heartworm Society (AHS) heartworm treatment protocol used in dogs in a recent study by Romito et al. entitled “Efficacy and tolerability of the American Heartworm Society therapeutic protocol in dogs affected by heartworm disease without caval syndrome.” Heartworm, Dirofilaria immitis, is one of the most common and important parasites in dogs, but also affects cats, as well as a myriad of other animals, including ferrets. This disease is totally preventable with the regular administration of macrocyclic lactone drugs; however, not every animal gets these preventives.

In this episode, we're diving into how to grow the herbs you'll actually use—and how to make the most of them in the kitchen. From choosing the right herbs for Central Florida gardens to cooking tips and health benefits, we've got your herb questions covered! Sources for Show Notes:   Find your local UF/IFAS Extension office:   https://sfyl.ifas.ufl.edu/find-your-local-office/   In Polk County, contact the Plant Clinic at 863-519-1041, polkmg@ifas.ufl.edu   Your Central Florida page https://centralfloridayard.substack.com/    Herbs in the Florida Garden https://gardeningsolutions.ifas.ufl.edu/plants/edibles/vegetables/herbs/ Herbs: A Series of Helpful Fact Sheets https://blogs.ifas.ufl.edu/polkco/2021/05/04/herbs-a-series-of-helpful-fact-sheets/ Homemade Potting Mix https://sfyl.ifas.ufl.edu/lawn-and-garden/homemade-potting-mix/ Advanced Seed Starting (info on scarification) https://gardeningsolutions.ifas.ufl.edu/care/planting/advanced-seed-starting/ Does Cilantro Taste Like Soap to You?  https://ourbloodinstitute.org/blood-matters/cilantro-tastes-like-soap/    Why Does Cilantro Taste Like Soap to Some People? https://www.britannica.com/story/why-does-cilantro-taste-like-soap-to-some-people    Clinical Efficacy and Tolerability of Lemon Balm (Melissa officinalis L.) in Psychological Well-Being: A Review https://pmc.ncbi.nlm.nih.gov/articles/PMC11510126/ Shopping for Health: Herbs and Spices https://edis.ifas.ufl.edu/publication/FS225  National Herb Day: 1st Saturday in May  National More Herbs, Less Salt Day: Aug 29 Podcast introduction and closing music: "Green Beans" by Big Score Audio.

Featuring slide presentations and related discussion from Dr Hanny Al-Samkari, Dr James B Bussel and Prof Nichola Cooper, including the following topics: Introduction (0:00) Clinical Manifestations and Initial Management of Immune Thrombocytopenia (ITP) — Dr Al-Samkari (10:24) Second- and Later-Line Therapies for ITP — Dr Bussel (1:00:51) Tolerability and Other Practical Considerations with Available Treatment Strategies for Persistent/Chronic ITP — Prof Cooper (1:28:08) CME information and select publications

Featuring an interview with Dr Raajit K Rampal, including the following topics: Clinical decision-making in the initiation and stopping of systemic therapy for myelofibrosis (MF) (0:00) Novel research strategies involving CDK4/6 inhibitors for MF (8:03) Implications of the JUMP study for clinical practice (10:00) Therapeutic switching strategies with JAK inhibitors for MF (12:17) Clinical rationale for the use of luspatercept and elritercept for MF (15:35) Emerging clinical data involving BET inhibitors for MF (16:57) Tolerability concerns with selinexor in patients with MF (20:01) Mechanism of and clinical data with the MDM2 inhibitor navtemadlin for MF (22:32) Additional novel strategies under clinical investigation for MF (25:52) Potential transformation of myeloproliferative neoplasms to acute myeloid leukemia (29:40) Management of polycythemia vera and essential thrombocythemia (34:27) General management principles for myeloproliferative neoplasms (37:53) CME information and select publications

Featuring an interview with Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:22) CME information and select publications

Featuring a slide presentation and related discussion from Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:31) CME information and select publications

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/ProactiveAdverseEffectManagementinmCRCImprovingTolerabilitytoOptimizePatientOutcomes/32945/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

“I genuinely think nurses and pharmacists need to know why these medicines are called hedgehog inhibitors so that we can, in fact, effectively educate our patients. Just because to date, this class has the weirdest name I've encountered, and I almost expect at this point that my patients are going to ask me about it. I think that we need to be informed that, just on, where do these names come from, why is it called this, and does it matter to my patient?” Andrew Ruplin, PharmD, clinical oncology pharmacist at Fred Hutchinson Cancer Center in Seattle, WA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about hedgehog pathway inhibitors.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 14, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learners will report an increase in knowledge related to hedgehog pathway inhibitors used for cancer treatment.  Episode Notes   Complete this evaluation for free NCPD.  ONS Podcast™ Pharmacology 101 series  ONS Voice articles: An Oncology Nurse's Guide to Targeted Therapy FDA Approves Glasdegib for AML in Adults Aged 75 or Older or Who Have Comorbidities Oncology Drug Reference Sheet: Glasdegib Understanding Precision Medicine Therapeutics ONS courses: Genomic Foundations for Precision Oncology ONS Cancer Biology™   ONS Guidelines™ and Symptom Interventions:  Diarrhea Fatigue ONS Huddle Card: Targeted Therapy ONS Learning Libraries: Oral Anticancer Medication Pain Management  Oral Chemotherapy Education Sheets American Association for Cancer Research article: Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia American Journal of Clinical Dermatology article: Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies Cureas article: Hedgehog Pathway Inhibitors: Clinical Implications and Resistance in the Treatment of Basal Cell Carcinoma International Journal of Molecular Sciences article: Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode  “Many patients unfortunately will have side effects with this class. I mean—and I know that's not controversial—but you actually find callouts in some of the kind of the national consensus guidelines. These treatments might not be tolerable for a decent number of patients. Some of these side effects can certainly reduce quality of life. Again, nothing that controversial here when we say it out loud, but just the frequency with which it occurs can make it quite difficult for some patients.” TS 9:13  “Certainly, based on what we said before, I think one of the easiest things to do for patients starting this class is to just make sure that they have really classical supportive medicines like antidiarrheals and antiemetics before they start treatment. Diarrhea, nausea occurred in about 20%–40% of patients across trials. So certainly patients should be aware of that risk. Again, not a controversial side effect, but it's just simple things we can do to make sure that our patients are quick to start treatment is to make sure that they have these medicines and they're educated on how to use them.” TS 11:21  “I think patients need to be aware that side effects, as I had mentioned before, can be especially frequent with this class. So for a patient, they need to be aware that communicating your needs to your oncology team is really crucial to their own ability to use these treatments with minimal interruptions.” TS 14:45  “I think that regardless of whoever is following up with our patients, though, as our arsenal of oral anticancer therapies does continue to expand, both nurses and pharmacists need to have specialized knowledge of these agents to be successful in their patient care roles.” TS 18:28  “When there are clear recommendations for reproductive health, as I summarized before with these agents, I obviously think we need to be aware of them and not just defer to these generic recommendations. Because if you just defer to, ‘Well, use barrier contraception and then for a week after your last dose,' you know, ‘Okay, it's not true with these agents.'” TS 24:37   

Dr. John Fleetham chats with Dr. Hedner and Dr. Schmickl about their articles “A Randomized Controlled Trial Exploring Safety and Tolerability of Sulthiame in Sleep Apnea" and  “Drug Therapy for Obstructive Sleep Apnea: Are We There Yet?” 

In this AANEM podcast, Dr. Stino interviews Dr. Allen on the groundbreaking ADHERE study, published in Lancet Neurology in 2024, which investigated efgartigimod for treating chronic inflammatory demyelinating polyneuropathy (CIDP). As the largest CIDP trial to date with 322 patients across 146 sites, it marked the first major study of a targeted biologic therapy in CIDP. The trial featured a unique two-stage design: An open-label response phase followed by a randomized controlled phase for responders. Dr. Allen explains the rationale behind targeting IgG in CIDP, despite its less clear antibody-mediated mechanism compared to myasthenia gravis. The study demonstrated a 66-70% response rate in the open-label phase, with significantly lower relapse rates compared to placebo in the randomized phase. This research represents a significant advancement in CIDP treatment options, offering a weekly subcutaneous administration that could reduce treatment burden compared to traditional therapies.

Featuring perspectives from Prof Andreas Hochhaus, Dr Michael J Mauro and Dr B Douglas Smith, moderated by Dr Mauro, including the following topics: Introduction (0:00) Up-Front Therapy for Chronic Myeloid Leukemia (CML) — Prof Hochhaus (2:45) Management of Relapsed CML, Including in Patients with a T315I Mutation — Dr Mauro (29:23) Tolerability and Other Practical Issues with Commonly Employed CML Therapies — Dr Smith (1:00:15) CME information and select publications

Featuring perspectives from Dr Priyanka Sharma and Dr Sara M Tolaney, including the following topics: Introduction: Metastatic Triple-Negative Breast Cancer (mTNBC) — The Patient Perspective (0:00) Selection and Sequencing of Antibody-Drug Conjugates (5:09) Dosing and Tolerability of Sacituzumab Govitecan; Use of Anthracyclines (14:39) Case: A woman in her early 60s with relapsed TNBC (HER2 2+) who experiences disease progression on T-DXd (Grade 2 interstitial lung disease) and receives sacituzumab govitecan — Shaachi Gupta, MD, MPH (22:04) Discussing Palliative and End-of-Life Care (32:40) PARP Inhibitors for TNBC with Somatic versus Germline Mutations; Cytopenias with PARP Inhibitors (37:53) The “Art of Oncology” — Building Trust with Patients and Family Members (45:05) Case: A woman in her mid 60s with recurrent TNBC with extensive chest wall involvement — Dr Gupta (48:44) Case: A man in his mid 40s with multiregimen-refractory AR-positive TNBC with an ERBB2 exon 20 insertion mutation — Dr Gupta (52:53) CME information and select publications

Featuring perspectives from Dr Joshua Brody, Dr Matthew Lunning and Dr Jason Westin, moderated by Dr Lunning, including the following topics: Introduction (0:00) Integration of Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Westin (1:34) Current Role of CAR T-Cell Therapy for Other B-Cell Lymphomas — Dr Lunning (21:17) Tolerability and Other Practical Considerations with CAR T-Cell Therapy — Dr Brody (40:15) CME information and select publications

Infinite Mobilization chapter 5 part ??

In episode 72 of Topline, hosts Sam, AJ, and Asad dive into the tricky balance between growing a business and staying profitable, with Uber and DoorDash as prime examples. The conversation also touches on the role of venture capital, the importance of having a motivated, driven team, and the nuances of different business models. Want more Topline? Join the Topline Slack channel to engage with hosts, guests, and other listeners and subscribe to Topline Newsletter. Secure your ticket to GTM2024 in Austin, TX (October 14 - 16).

CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/frontline-fixed-duration-therapy-in-cll-improving-outcomes-and-tolerability/26495/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.

Featuring perspectives from Dr Joshua Brody, Dr Ian W Flinn and Dr Tycel Phillips, including the following topics: Introduction: CD3 Bispecific Antibodies in the Community Oncology Setting (0:00) Integration of Bispecific Antibody Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Phillips (18:13) Current and Future Role of Bispecific Antibodies in Follicular Lymphoma and Other B-Cell Lymphomas — Dr Flinn (41:20) Tolerability and Other Practical Considerations with the Use of Bispecific Antibody Therapy — Dr Brody(50:49) CME information and select publications

Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial  Nature Medicine The safety and tolerability of racemic ketamine may be improved if given orally, as an extended-release tablet (R-107), compared with other routes of administration. In this phase 2 multicenter clinical trial, male and female adult patients with treatment-resistant major depression (TRD) and Montgomery–Asberg Depression Rating Scale (MADRS) scores ≥20 received open-label R-107 tablets 120 mg per day for 5 days and were assessed on day 8 (enrichment phase). On day 8, responders (MADRS scores ≤12 and reduction ≥50%) were randomized to receive double-blind R-107 doses of 30, 60, 120, or 180 mg, or placebo, twice weekly for 12 weeks. Nonresponders on day 8 exited the study. Tolerability was excellent, with no changes in blood pressure, minimal reports of sedation, and minimal dissociation. The most common adverse events were headache, dizziness, and anxiety. R-107 tablets were effective, safe, and well tolerated in patients with TRD, enriched for initial response to R-107 tablets.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

In this episode:Why it's so difficult to find an effective solution to chronic low back painBreaking down common myths about chronic low back pain How beliefs about back pain can negatively impact on recoveryThe problem with existing treatment approaches The Pain Puzzle is an educational series designed to bring you the latest science underpinning effective management of chronic low back pain. This series will help you understand chronic low back pain and how you can use mind-based therapies to better manage your pain and get back to the life you love.This episode of the Pain Puzzle is brought to you by Relio.Relio is a science-backed digital program that combines cutting-edge pain science education with the effective power of clinical hypnosis to get to the root cause of your pain.Website: reliohealth.comApp storeGoogle Play storeReferences:Magnetic resonance imaging of the lumbar spine in people without back pain.Systematic literature review of imaging features of spinal degeneration in asymptomatic populations. Clinical Pain Management: A Practical Guide. What happens to the lower lumbar spine after marathon running: a 3.0 T MRI study of 21 first-time marathoners.Relationship of significance of wound to pain experienced.Non-specific low back pain.Chronic Pain. Efficacy, Tolerability, and Dose-Dependent Effects of Opioid Analgesics for Low Back Pain: A Systematic Review and Meta-analysis. Spinal cord stimulation for low back pain. Cochrane Database of Systematic Reviews 2023.Clinical Care Guidelines for Chronic Low Back Pain.Disclaimer:The content in this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or qualified healthcare practitioner. Never disregard professional medical advice or delay seeking it because of topics discussed in this podcast.

Optimizing Sacituzumab Govitecan Tolerability in TNBC With Early Management: Antonio Llombart, MD by i3 Health

In this episode of CUBIST, the hosts discuss a study titled “Head Injury Treatment with Healthy and Advanced Dietary Supplements, a pilot randomized controlled trial of the tolerability, safety, and efficacy of branched chain amino acids in the treatment of concussion in adolescents and young adults.” The study was authored by Dr. Daniel Corwin and his colleagues. and was published in the Journal of Neurotrauma in April of 2024. Article Citation: Corwin, D. J., Myers, S. R., Arbogast, K. B., Lim, M. M., Elliott, J. E., Metzger, K. B., LeRoux, P., Elkind, J., Metheny, H., Berg, J., Pettijohn, K., Master, C. L., Kirschen, M. P., & Cohen, A. S. (2024). Head Injury Treatment With Healthy and Advanced Dietary Supplements: A Pilot Randomized Controlled Trial of the Tolerability, Safety, and Efficacy of Branched Chain Amino Acids in the Treatment of Concussion in Adolescents and Young Adults. Journal of neurotrauma, 41(11-12), 1299–1309. https://doi.org/10.1089/neu.2023.0433 Article LINK: https://pubmed.ncbi.nlm.nih.gov/38468511/ CUBIST is a podcast for health care providers produced by the Traumatic Brain Injury Center of Excellence. We discuss the latest research on traumatic brain injury most relevant to patient care. For more about TBI, including clinical tools, go to www.health.mil/TBICoE or email us at dha.TBICoEinfo@health.mil. The views and opinions of findings and or devices discussed in this podcast are those of the host, subject matter experts, and or guests. Facts represented constitute our understanding at the time of the podcast, whereas updated factual information may be developed. They should not be construed as pronouncing an official Department of Defense's position, policy, decision, or endorsement. The hosts and guests of CUBIST may be defense contract personnel who support TBICoE. The status of all hosts and guests will be identified during introductions to the podcast. Our theme song is “Upbeat-Corporate' by WhiteCat, available and was used according to the Creative Commons Attribution-Noncommercial 4.0 license.

In this episode of CUBIST, the hosts discuss a study titled “Head Injury Treatment with Healthy and Advanced Dietary Supplements, a pilot randomized controlled trial of the tolerability, safety, and efficacy of branched chain amino acids in the treatment of concussion in adolescents and young adults.” The study was authored by Dr. Daniel Corwin and his colleagues. and was published in the Journal of Neurotrauma in April of 2024. Article Citation: Corwin, D. J., Myers, S. R., Arbogast, K. B., Lim, M. M., Elliott, J. E., Metzger, K. B., LeRoux, P., Elkind, J., Metheny, H., Berg, J., Pettijohn, K., Master, C. L., Kirschen, M. P., & Cohen, A. S. (2024). Head Injury Treatment With Healthy and Advanced Dietary Supplements: A Pilot Randomized Controlled Trial of the Tolerability, Safety, and Efficacy of Branched Chain Amino Acids in the Treatment of Concussion in Adolescents and Young Adults. Journal of neurotrauma, 41(11-12), 1299–1309. doi.org/10.1089/neu.2023.0433 Article LINK: pubmed.ncbi.nlm.nih.gov/38468511/ CUBIST is a podcast for health care providers produced by the Traumatic Brain Injury Center of Excellence. We discuss the latest research on traumatic brain injury most relevant to patient care. For more about TBI, including clinical tools, go to www.health.mil/TBICoE or email us at dha.TBICoEinfo@health.mil. The views and opinions of findings and or devices discussed in this podcast are those of the host, subject matter experts, and or guests. Facts represented constitute our understanding at the time of the podcast, whereas updated factual information may be developed. They should not be construed as pronouncing an official Department of Defense's position, policy, decision, or endorsement. The hosts and guests of CUBIST may be defense contract personnel who support TBICoE. The status of all hosts and guests will be identified during introductions to the podcast. Our theme song is “Upbeat-Corporate' by WhiteCat, available and was used according to the Creative Commons Attribution-Noncommercial 4.0 license.

Featuring perspectives from Dr John N Allan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, including the following topics: Introduction (0:00) First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (11:44) The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL (18:08) Toxicities and Other Practical Considerations with Venetoclax-Based Treatment (25:17) The Selection and Sequencing of Therapies for Relapsed/Refractory CLL (35:45) The Tolerability of Available Bruton Tyrosine Kinase (BTK) Inhibitors (40:43) The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax (48:48) Bispecific Antibodies as a Treatment Option for Non-Hodgkin Lymphoma (1:04:19) Cytokine Release Syndrome and Neurotoxicity with Bispecific Antibodies (1:06:25) Other Tolerability and Toxicity Issues with Bispecific Antibody Therapy (1:10:44) Bispecific Antibodies for the Management of Follicular Lymphoma (1:18:19) The Role of Bispecific Antibody Therapy in the Treatment of Diffuse Large B-Cell Lymphoma (1:24:17) Other Practical Considerations with the Use of Bispecific Antibodies (1:40:59) NCPD information and select publications

Featuring perspectives from Dr William J Gradishar, Dr Virginia Kaklamani, Dr Erica Mayer and Dr Seth Wander, including the following topics: Introduction (0:00) Addition of Ovarian Function Suppression (OFS) to Adjuvant Endocrine Therapy for Premenopausal Patients with Hormone Receptor (HR)-Positive Breast Cancer — Dr Gradishar (4:49) Case: A woman in her mid 20s with HR-positive, HER2-positive intraductal carcinoma (IDC) who received ovarian suppression with TAC chemotherapy and concurrent trastuzumab/pertuzumab followed by tamoxifen (30:48) Case: A woman in her late 30s with HR-positive, HER2-negative IDC and no nodal involvement who received postoperative chemoradiation therapy followed by tamoxifen and is considering ovarian suppression (39:31) Role of OFS in Preserving Fertility and/or Ovarian Function in Premenopausal Patients – Dr Mayer (44:55) Case: A woman in her early 30s with HR-positive, HER2-positive (IHC 3+) IDC recommended to receive perioperative TCHP who is interested in fertility preservation (1:11:15) Case: A woman in her mid 30s presenting with ER-positive, HER2-negative breast cancer during early pregnancy who received preoperative TAC and had pathologic complete response at surgery (1:14:18) Tolerability and Toxicity of OFS – Dr Kaklamani (1:21:21) Case: A woman in her mid 30s, uninterested in fertility preservation, who received chemotherapy and TAC followed by tamoxifen and abemaciclib for ER-positive, HER2-negative breast cancer (1:39:42) Case: A premenopausal woman in her late 40s with a 3.6-cm breast tumor and a Recurrence Score (RS) of 26 who becomes amenorrheic with chemotherapy and TC (1:43:32) Other Practical Considerations in the Application of OFS – Dr Wander (1:46:29) Case: A woman in her early 50s with HR-positive, HER2 IHC 2+ invasive lobular carcinoma and a RS of 15 who declined chemotherapy and opted to stop adjuvant leuprolide after 1 year (1:59:56) Case: A woman in her early 40s with HR-positive, HER2 IHC 1+ breast cancer who has no interest in fertility preservation and significant residual disease at surgery (2:14:06) CME information and select publications

Featuring perspectives from Ms Deanna A Griffie, Ms Caroline Kuhlman, Dr Manish A Shah and Dr John Strickler, including the following topics: Introduction (0:00) The Current Role of Anti-PD-1/PD-L1 Antibodies in the Management of Nonmetastatic Gastroesophageal Cancers (11:30) The Potential Role of Immune Checkpoint Inhibitors (ICIs) as Neoadjuvant Therapy for Patients with Gastric/Gastroesophageal Junction Cancer (20:53) First-Line Therapy for Metastatic Gastroesophageal Cancers (36:16) The Potential Role of Therapy Targeting Claudin 18.2 for Gastroesophageal Cancers (42:16) Targeted Therapies for HER2-Positive Gastroesophageal Cancers (51:42) Selection of Appropriate Candidates with Localized Colorectal Cancer (CRC) for Adjuvant Therapy (1:14:24) The Current Role of ICIs in the Treatment of Metastatic CRC (mCRC) (1:23:32) Tolerability and Other Practical Considerations with ICIs (1:25:57) The Role of TAS-102/Bevacizumab in the Management of Relapsed/Refractory (R/R) mCRC (1:36:14) The Potential Role of KRAS-Targeted Therapy in the Management of mCRC (1:44:36) NCPD information and select publications

Featuring perspectives from Ms Meetal Dharia, Dr Robert L Ferris, Dr Robert Haddad and Ms Lynsey P Teulings, including the following topics: Introduction (0:00) The Biology of Head and Neck Cancer (15:41) The Multidisciplinary Treatment of Head and Neck Cancer (18:14) Ongoing Screening and Prevention After Potentially Curative Therapy for Head and Neck Cancer (33:03) Radiation Therapy and Chemotherapy Side Effects (41:02) The Potential Short- and Long-Term Effects of Surgery for Head and Neck Cancer (49:50) Emerging Treatment Strategies Aimed at Improving Outcomes Associated with Localized or Locally Advanced Head and Neck Cancer (56:46) Tolerability Considerations with Xevinapant (1:06:13) The Established Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Advanced Head and Neck Cancer (1:17:35) Newly Approved Immunotherapeutic Strategies for Nasopharyngeal Carcinoma (1:19:27) The Tolerability of Immune Checkpoint Inhibitors (1:24:09) NCPD information and select publications

In the first episode of a special daily series during the 2024 ASCO Annual Meeting, Dr. John Sweetenham shares highlights from Day 1, including exciting data on the CROWN trial in NSCLC, the ASC4First study in chronic myeloid leukemia, and the effects of high-deductible health plans on cancer survivorship. TRANSCRIPT Dr. John Sweetenham: I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. I'm delighted to bring you a special series of daily episodes from the 2024 ASCO Annual Meeting and to share my top takeaways on selected abstracts.   Today, I'll be reviewing exciting new data in chronic myeloid leukemia, remarkable outcomes for patients with ALK-positive non-small cell lung cancer, and a compelling study on the effects of high deductible health plans on cancer survivorship.   My disclosures are available in the transcript of this episode.   LBA6500, the ASC4FIRST trial, is a phase 3 combination of asciminib with the current standard of care tyrosine kinase inhibitors, those being imatinib, nilotinib, dasatinib and bosutinib for the first line treatment of patients with chronic myeloid leukemia. The data from this large multinational study, conducted in 29 countries, were presented by Dr. Timothy Hughes from the Royal Adelaide Hospital in Australia. Some patients with chronic phase CML respond well to tyrosine kinase inhibitor therapy, and about one-third may eventually be able to stop therapy and will remain in remission, the so-called treatment free remission or TFR. Unfortunately, almost half of patients eventually need to change therapy due to resistance and intolerance, and most patients will need to remain on therapy for many years, possibly for life.  Asciminib is the first BCR-ABL1 inhibitor to specifically target the ABL myristate pocket or STAMP and was designed to be highly potent but also highly specific, thus minimizing side effects and toxicity. In this large trial, which is the first randomized head-to-head comparison of asciminib with other tyrosine kinase inhibitors, 405 patients were randomized 1:1 to receive either asciminib at a dose of 80 milligrams daily or another investigator-selected TKI. The groups were well balanced for all patient characteristics, including ELTS risk. The primary objectives of the study were to compare the major molecular response rate at 48 weeks with an additional analysis for the patients who received imatinib as the investigator-selected TKI. With median follow-up at 16.3 months for patients receiving asciminib and 15.7 months for those receiving the other TKIs, the 48-week MMR rates were 68% for asciminib compared with 49% for the other investigators-selected TKIs.  The rates of MR4 after 48 weeks, a deep molecular response which is a prerequisite to be considered for treatment free remission, were 39% for asciminib compared to 21% for the investigator-selected TKI. Tolerability and safety were excellent for asciminib, with only 5% discontinued due to toxicity compared to 10% for the other TKI arm. Frequently observed toxicities with asciminib included thrombocytopenia and neutropenia. The investigators concluded that asciminib is the only agent to show a statistically significant improvement in efficacy and toxicity in this patient group when compared with all other TKIs, and that asciminib has the potential to become the preferred standard of care for the first line treatment of CML. Follow-up on the study continues, but there is no question that these are exciting and probably practice-changing results.  The next exciting study, LBA8503, was presented by Dr. Benjamin Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia. This presentation was an update of the CROWN study for patients with previously untreated advanced ALK-positive non-small cell lung cancer. Lorlatinib is a third-generation brain-penetrating ALK inhibitor which was compared with crizotinib in the CROWN-3 study. This phase 3 study enrolled 296 patients randomly assigned to lorlatinib 100 milligrams once daily or crizotinib 250 milligrams twice daily. The interim results showed a 72% reduction in the risk for progression or death with lorlatinib compared with crizotinib and formed the basis for the March 2021 FDA approval of the drug for metastatic ALK positive non-small cell lung cancer. A subsequent post hoc analysis at three years showed continued progression free survival benefit with lorlatinib compared with crizotinib.  Earlier today, Dr. Solomon presented a further post hoc analysis of the study at 60.2 months of median follow-up. Among the entire patient population, the median PFS was not reached with lorlatinib compared with 9.1 months with crizotinib. At 60 months, the PFS rate was 60% with lorlatinib compared with only 8% with crizotinib. The PSF benefits with lorlatinib were seen across all patient subgroups. The improved control of central nervous system metastatic disease, which was observed in the earlier reports, has been confirmed in this recent analysis. Among those patients with baseline brain metastases, the median PFS with lorlatinib was not yet reached compared with six months with crizotinib. More than half of patients with baseline brain metastases were progression free at 60 months.   But the benefit of lorlatinib is certainly not confined to patients with brain metastases. Lorlatinib also significantly improved progression-free survival among patients without metastases. At 60 months, 63% of patients without baseline brain metastases assigned to lorlatinib were progression free, compared with only 10% of those assigned crizotinib. These are remarkable results. As Dr. Solomon stated in his conclusion, 60% of patients on lorlatinib are still progression free and 92% are progression free in the brain. No new safety signals were seen and the improved efficacy over crizotinib was seen across all risk groups. These results are unprecedented in patients with ALK-positive non-small cell lung cancer.   Concerning data were presented today by Dr. Justin Barnes from Washington University. Dr. Barnes presented results from a retrospective study in Abstract 11005 which showed whether a patient with cancer has high-deductible health insurance can play a role in their survival. Although previous studies have shown care disparities for those with high-deductible plans, this report focuses specifically on effects on survival and concludes that cancer survivors with high-deductible health plans had a greater risk of mortality both overall and from cancer. High-deductible insurance was defined as costing between $1,200 and $1,350 annually for individual insurance, or between $2,400 and $2,700 annually for a family plan. Investigators used data from the U.S. National Center for Health Statistics National Health Interview Survey and linked them to files from the National Death Index to determine mortality rates. Included were more than 147,000 respondents aged between 18 and 84 years who did not have Medicaid. Among these individuals, 5.9% were cancer survivors. The concern for cancer survivors with these plans is that in addition to recurrence that could require costly treatments, there might be issues related to survivorship. Investigators found that overall survival was worse for those with a cancer diagnosis coupled with high-deductible health insurance, with a hazard ratio of nearly 1.5.   But when the researchers reviewed data from the general population without a history of cancer, they didn't find any association between high-deductible health insurance and outcomes. According to Dr. Barnes, the leading hypothesis is that patients with cancer who have a high-deductible plan delay workup for a potential new or recurrent cancer diagnosis or postpone or avoid other care. The results also indicated that survival among certain subgroups, such as non-Hispanic white patients, patients with higher incomes, and patients with at least a college or high school education, was worse for those with a high-deductible health plan, not the groups who are typically impacted by care disparities. It is possible that these individuals are more likely to select high-deductible health plans and that having these plans might counteract what might otherwise be adequate access to care.  A key take-home from this analysis is that cancer patients and survivors, whatever their racial, ethnic, or socioeconomic status, should have access to health plans with low deductibles and should be informed of the potential risks of their long-term health and survival when covered by high-deductible plans.   Join me again tomorrow to hear more top takeaways from ASCO24. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review and subscribe wherever you get your podcasts.   Disclaimer:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Facebook  ASCO on LinkedIn    Disclosures: Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness

Featuring an interview with Dr Elias Jabbour, including the following topics: Evolution of research and therapeutic options for acute lymphoblastic leukemia (ALL) (0:00) Clinical and biological characteristics of ALL and implications for prognosis and disease management (6:36) Case: A 48-year-old woman with newly diagnosed Philadelphia chromosome-positive (Ph-positive) ALL attains complete remission with ponatinib/blinatumomab (14:03) Tolerability and improved quality of life with the chemotherapy-free combination of ponatinib and blinatumomab (24:17) Case: A 38-year-old man with newly diagnosed Ph-positive ALL experiences a complete molecular response with induction hyper-CVAD and ponatinib (27:10) CME information and select publications

CME credits: 0.50 Valid until: 14-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/safety-and-tolerability-of-changing-covalent-btk-inhibitor-treatment-in-a-patient-intolerant-to-ibrutinib-or-acalabrutinib/24454/ Selection of Bruton's tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.

In this episode of Quah (Q & A), Sal, Adam & Justin coach four Pump Heads via Zoom. Mind Pump Fit Tip: BUILD MUSCLE to drastically improve your health! (1:45) Risk vs. reward when it comes to kids and contact sports. (15:19) Dispelling misinformation on Sal's tattoo. (19:25) Adam at his lowest weight since competing days. (20:42) Educating the audience on the accuracy of body fat tests. (27:55) The Happy Drops from Organifi are CRUSHING! (32:04) A wedding reception gone TERRIBLY wrong. (36:43) That one-time Justin got stuck on a rollercoaster. (37:47) Adam's embarrassing text. (39:08) Highlighting how we misunderstand studies or data. (43:06) Storytelling and teaching lessons. (46:05) How to get 10 clients in 10 days. (50:40) Shout out to Hippy Feet socks! (51:23) #ListenerLive question #1 – What sort of training/conditioning would you suggest aiding with dance lifts? (57:23) #ListenerLive question #2 – Would you have any suggestions on how to program for 75 Hard to finish strong and not be worn out or injured? (1:09:21) #ListenerLive question #3 – How do I work on body parts that are lagging? (1:24:10) #ListenerLive question #4 – I've had a string of injuries, any advice on how to remedy this? (1:37:52) Related Links/Products Mentioned Ask a question to Mind Pump, live! Email: live@mindpumpmedia.com See and hang out with Mind Pump, LIVE! Saturday, June 15 · 1pm PDT Bellagio Las Vegas. Click the link here for more details. Visit Organifi for the exclusive offer for Mind Pump listeners! **Promo code MINDPUMP at checkout for 20% off. May 10-12th, Mother's Day Weekend - Buy 1 Get 1 Free Organifi Harmony Plus Free Shipping ** Exclusively for Mind Pump Listeners, NCI is offering access to their free guide on learning to find, close and retain 10 clients in 10 days.  May Promotion: MAPS Strong | MAPS Powerlift 50% off! ** Code MAY50 at checkout ** Trends in nutrition, lifestyle, and metabolic disease in the United States from 1900 onwards Effects of macronutrient intake in obesity: a meta-analysis of low-carbohydrate and low-fat diets on markers of the metabolic syndrome Strength Of Grip Declines In Young Adults Mind Pump #1877: Obesity, It's Not Your Genetics Guardian Caps: Are the soft-shelled football helmet covers effective at limiting head injuries? Mind Pump #2320: Throw Away The Scale! An 8-Week Randomized, Double-Blind Trial Comparing Efficacy, Safety, and Tolerability of 3 Vilazodone Dose-Initiation Strategies Following Switch From SSRIs and SNRIs in Major Depressive Disorder The wedding menu that put 80 guests in hospital and left more than 100 people vomiting is revealed - as one attendee says men and women were given different food, but all ended up sick Giving Birth Later in Life Linked to Longer Life | TIME Children's Books by Andy Frisella The Very Hungry Caterpillar book hand2mind Numberblocks Friends One to Five Figures, Toy Figures Collectibles, Small Cartoon Figurines for Kids, Mini Action Figures, Character Figures, Play Figure Playsets, Imaginative Play Toys All Hippy Feet Products - American Made & Eco-Friendly Body Brokers | Rotten Tomatoes California fails to track how billions are spent to fight homelessness Visit Seed for an exclusive offer for Mind Pump listeners! **Promo code 25MINDPUMP at checkout for 25% off your first month's supply of Seed's DS-01® Daily Synbiotic** Improve Your Overhead Press & Build Your Shoulders with Unilateral Kettlebell Carries – Mind Pump TV Chaos Band Training: How To, Benefits, Variations - Muscle & Fitness Using The Earthquake Bar | Westside Barbell Mind Pump #2290: Becoming A Better Man With Jason Khalipa Mind Pump #2220: How To Stay Consistent With Your Workouts Ask Mind Pump Mind Pump #2322: Why Your Butt Won't Grow Mind Pump #1872: Eight Benefits Of Lifting With Light Weight Sore muscles…what does it mean? – Mind Pump Blog Mind Pump #2312: Five Steps To Bounce Back From Overtraining MAPS Prime Pro Webinar Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned Drew Canole (@drewcanole) Instagram Mark Hyman, M.D. (@drmarkhyman) Instagram Mike Matthews (@muscleforlifefitness) Instagram Andy Frisella (@andyfrisella) Instagram Joe DeFranco (@defrancosgym)  Instagram James Smith (@smittydiesel)  Instagram Jason Khalipa (@jasonkhalipa) Instagram  

Featuring perspectives from Ms Marianne J Davies, Dr Alexander I Spira, Ms Jillian Thompson and Dr Helena Yu, including the following topics: Introduction (0:00) The Importance of EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) (7:02) The Role of Osimertinib in Managing Localized and Locally Advanced NSCLC with an EGFR Mutation (11:58) Established First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (32:38) Newly Approved and Promising Investigational Approaches to First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (37:45) Common Toxicities Associated with Amivantamab (45:07) The Current and Future Management of Progressive NSCLC with an EGFR Mutation (55:06) Tolerability and Other Practical Considerations with HER3-DXd (1:01:06) Treatment for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations (1:18:26) CME information and select publications

Featuring perspectives from Dr Carlos M de Castro III, Prof Alexander Röth and Dr Ilene Ceil Weitz, including the following topics: Introduction: A Paroxysmal Nocturnal Hemoglobinuria (PNH) Audio Primer for General Medical Oncologists (0:00) Biology and Current Clinical Management of PNH (36:35) Future Directions in PNH Management (55:34) Tolerability and Other Practical Considerations with Available and Emerging Treatments for PNH (1:14:26) CME information and select publications

This April, Oncology Data Advisor is raising awareness for Esophageal Cancer Awareness Month. In this interview, Oncology Data Advisor Editorial Board and Fellows Forum members Dr. Joseph Kalis, Dr. Matthew Hadfield, and Dr. Samuel Kareff discuss rising trends, treatment advances, and emerging management strategies for esophageal cancer, including the following: • The rising rate of adenocarcinoma in the context of pre-existing esophageal dysplasia and Barrett esophagus • Risk factors such as tobacco and alcohol • The roles of healthy eating and smoking cessation in esophageal cancer prevention • How the rise of immunotherapies such as pembrolizumab, nivolumab, and trastuzumab have changed practice • This month's approval of fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2 (HER2)–positive solid tumors • Lifestyle interventions such as following the Mediterranean diet and United States Preventive Services Task Force (USPSTF) exercise guidelines that can make maximize tolerability of therapy

Featuring perspectives from Dr Robin (Katie) Kelley and Dr Mark Yarchoan, including the following topics:  Introduction: Interdisciplinary Management of Hepatocellular Carcinoma (HCC) in the Community (General Medical Oncology) Setting — Radiology, Hepatology, Pathology Support (0:00) Potential Role of Anti-PD-1/PD-L1 Antibodies in the Care of Patients with Early- and Intermediate-Stage HCC — Dr Yarchoan (8:09) HCC Rounds (22:07) Tolerability and Other Practical Considerations with the Use of Immune Checkpoint Inhibitors for Advanced HCC and Biliary Tract Cancers (BTCs) — Dr Kelley (39:25) Faculty Survey (49:19) BTC Rounds (52:19) CME information and select publications   

In this episode, we explore the unconventional yet promising treatment modality of using broad-spectrum micronutrient formulas in mental health care. We discuss the research and clinical trials that have been undertaken to test combinations of vitamins and minerals, focusing on their safety and efficacy. What are the potential side effects of using broad-spectrum micronutrient formulas? Faculty: Amelia Villagomez, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Broad-Spectrum Micronutrients (BSMs) for Mental Health: What You Need to Know for Clinical Use BSMs: Safety and Tolerability

Trial of the Week: Levetiracetam Rapid IV Push Special Guest: Olivia Morgan, PharmD, BCCCP, BCGP   I'm joined by Olivia Morgan to discuss her first author 2020 Neurocritical Care article entitled “Safety and Tolerability of Rapid Administration Undiluted Levetiracetam.” We review previous administration techniques and discussing how this study came to be before highlighting all the findings from this Trial of the Week. Then we discuss how the protocol has changed since this study, administering other ASM via rapid IV push, and much, much more.   Reference list:  https://pharmacytodose.files.wordpress.com/2024/03/keppra-rapid-ivp-references.pdf   PharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

The latest disruptors in regenerative skincare are exosomes. But are they effective and more importantly, are they safe?  We sit down with Dr. Sarayna Wyles, M.D., Ph.D., a dermatologist with expertise in regenerative medicine and a keen focus on skin aging. As to her impressive credentials, she provides care at the Mayo Clinic and her research lab studies the role of cellular senescence in age-related skin disease and wound healing.Key Points:Understanding Exosomes: Discover the role of exosomes, the extracellular vesicles acting as messengers that facilitate crucial signals within the body. Think of them as the FedEx or UPS of cellular communication.The Source Matters: Dr. Wyles sheds light on the significance of the exosome source, whether derived from platelets, mesenchymal stem cells, or other body fluids. Learn how to ensure the safety and reliability of exosomes to avoid potential risks.Skin Regeneration Benefits: Explore the various benefits of exosomes in skin tissue regeneration, from collagen synthesis to inflammation regulation. Dr. Wyles discusses how topical exosomes could potentially revolutionize the aesthetics market.Game-Changing Accessibility: Unlike traditional regenerative skin treatments with limited efficacy and high costs, discover how topical exosome products could provide consistent regenerative effects for all patients, including those with diverse skin tones.Topical Applications: Dr. Wyles presents a recent study showcasing the effects of (plated) Skin Science's topical exosomes on collagen. Gain insights into the exciting possibilities for skin rejuvenation.Tune in to explore the potential game-changers in regenerative skincare. Are exosomes safe, and do they really work? Join us to find out! Additional Studies:Efficacy and Tolerability of Topical Platelet Exosomes for Skin Rejuvenation: Six-Week Results - PubMed (nih.gov) Safety and efficacy of human platelet extract in skin recovery after fractional CO2 laser resurfacing of the face: A randomized, controlled, evaluator-blinded pilot study - PubMed (nih.gov) Effect of Topical Platelet Extract Daily Serum as a Cosmetic Product to Reduce Facial Redness - PubMed (nih.gov) A Comparative Study of Two Topical Treatments for Photoaging of the Hands - PubMed (nih.gov) Exosomes: the latest in regenerative aesthetics - PubMed (nih.gov)Shop the Show:(plated) INTENSE Serumhttps://platedskinscience.com/products/intense(plated) DAILY Serumhttps://platedskinscience.com/products/daily*we do not receive commission from the sale of these products and are providing links for convenience only

We have a panel discussion with authors Albert Wiegman and Frederick Raal and Editorialist Raul Santos as they discuss the original research articles "Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia" and "Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial." For the episode transcript, visit: https://www.ahajournals.org/do/110.1161/podcast.20240129.812328

At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more!

Cariprazine may be a good option for pediatric patients with schizophrenia and bipolar I disorder. Listen as Dr. Rosenberg summarizes study findings, which may broaden your options with children and adolescents. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 11 Safety and Tolerability of Cariprazine in Pediatric Patients

Commentary by Dr. Valentin Fuster

At this year's European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, Dr. Kevin Kalinsky, Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University, presented the results of real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line or later treatment of metastatic triple-negative breast cancer (TNBC). In this interview, he gives us further insight to the results he shared and what these results could mean for the future of the TNBC treatment landscape.

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners. This episode covers the field of critical psychiatry with Dr. Elia Abi-Jaoude and Lucy Costa. Dr. Abi-Jaoude is a staff psychiatrist at The Hospital for Sick Children and Assistant Professor and Clinician Investigator in the Department of Psychiatry at the University of Toronto in Toronto, Canada. Lucy Costa is Deputy Executive Director of the Empowerment Council, a voice for clients of mental health and addiction services primarily at the Centre for Addiction and Mental Health in Toronto.   While this topic could be very philosophical and expansive, we are going to focus our discussion by considering the practical implications of this field on psychiatric practice. What do you need to know about critical psychiatry as a trainee, and how might it impact your clinical practice?   The learning objectives for this episode are as follows: By the end of this episode, the listener will be able to… Define the term critical psychiatry and describe how the field has evolved over time Review core principles of critical psychiatry and apply them to a clinical situation Understand the potential benefits and harms of critical psychiatry and where the field is headed   Guests: Dr. Eila Abi-Jaoude and Lucy Costa   Hosts: Dr. Gaurav Sharma (PGY5), Dr. Nikhita Singhal (PGY5), Dr. Monisha Basu (PGY2), and Saja Jaberi (IMG)   Audio editing by: Gaurav Sharma   Show notes by: Gaurav Sharma and Nikhita Singhal   Conflicts of interest: Neither of our guests nor hosts have declared any conflicts of interest related to this topic. Interview content: Introduction - 00:13 Learning objectives - 02:35 Defining critical psychiatry - 03:33 How our experts got involved in critical psychiatry and incorporate it into their work - 04:50 What are some of the questions critical psychiatry tries to answer? - 15:07 Why care about critical psychiatry and “holding truths lightly”? - 23:55 Principles of critical psychiatry - 24:55 Applying critical psychiatry principles to a case - 32:40 Potential benefits and harms of a critical psychiatry approach - 41:49 Future directions for critical psychiatry - 58:29 Review of learning objectives and summary - 1:01:30 End credits - 1:03:17   Resources: Critical Psychiatry Textbook Restoring Study 329  Psych Debate 14 | Critical Psychiatry and Diagnosis   References: Barkil-Oteo A. Collaborative care for depression in primary care: how psychiatry could "troubleshoot" current treatments and practices. Yale J Biol Med. 2013 Jun 13;86(2):139-46. Craddock N, Mynors-Wallis L. Psychiatric diagnosis: impersonal, imperfect and important. The British Journal of Psychiatry. 2014;204(2):93-95. doi:10.1192/bjp.bp.113.133090 Kirsch I. The emperor's new drugs: medication and placebo in the treatment of depression. Handb Exp Pharmacol. 2014;225:291-303. doi:10.1007/978-3-662-44519-8_16 Middleton H, Moncrieff J. Critical psychiatry: a brief overview. BJPsych Advances. 2019;25(1):47-54. doi:10.1192/bja.2018.38 O'Donoghue T, Crossley J. A critical narrative analysis of psychiatrists' engagement with psychosis as a contentious area. Int J Soc Psychiatry. 2020 Nov;66(7):724-730. doi: 10.1177/0020764020934516 Samara MT, Dold M, Gianatsi M, et al. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. JAMA Psychiatry. 2016;73(3):199–210. doi:10.1001/jamapsychiatry.2015.2955   Important figures in the history of anti-psychiatry and critical psychiatry (discussion edited from episode for length): Anti-Psychiatrists: R. D. Laing (UK) Thomas Szasz (USA) Michel Foucault (France)   Critical Psychiatrists: Joanna Moncrieff (UK) Suman Fernando (UK) Sami Tamini (UK) Pat Bracken (UK) Derek Summerfield (UK) Sandra Steinguard (USA) Critical Psychiatry Network  (International Email List)   For more PsychEd, follow us on Twitter (@psychedpodcast), Facebook (PsychEd Podcast), and Instagram (@psyched.podcast). You can provide feedback by email at psychedpodcast@gmail.com. For more information, visit our website at psychedpodcast.org.

EXPIRING ON TUESDAY, NOVEMBER 14, 2023! This case-based podcast presented by i3 Health brings together two leading experts, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, who will examine recent clinical advances and new opportunities in the management of SCLC and discuss key clinical questions engendered by recent advances in treatment and the need for individualized care. Listen now! Click here to claim CME/NCPD/CPE credit: i3health.com/sclc-treatment

Recently, Dr. Henry Park, Chief of Thoracic Radiotherapy at Smilow Cancer Network of Yale School of Medicine, served as faculty for i3 Health's CME/NCPD/CPE–approved activity, Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer (SCLC). This month, numerous updates in the use of radiotherapy for SCLC were presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting. In this interview, Dr. Park outlines the most significant updates presented at ASTRO and how he plans to incorporate them into the treatment of patients with SCLC. At the end of the interview, stay tuned to hear Dr. Park's full presentation and claim credit at https://www.i3health.com/course-information/video-viewpoint-strategy-session-optimizing-treatment-selection-sequencing-and-tolerability-in-small-cell-lung-cancer.

Inside the Issue: Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management | Faculty Presentation 2: Tolerability and Other Practical Considerations with Bispecific Antibodies for MM CME information and select publications  

Neste episódio falamos de: Depressão e probióticos Quais Cepas são Psicobioticas Neuroinflamação Adoçantes e risco de doenças do coração Banho de flloresta Processamentos Top Down e Bottom Up Detox de R1talina e Neuroproteção Homens que são muito exigente Dose exata da cafeína Artigos citados: Suran M. Sugar Substitutes Don't Help Weight Control and May Increase Risk of Heart Disease and Diabetes, WHO Warns. JAMA. Published online June 14, 2023. doi:10.1001/jama.2023.10967 Braga J, Lepra M, Kish SJ, et al. Neuroinflammation After COVID-19 With Persistent Depressive and Cognitive Symptoms. JAMA Psychiatry. Published online May 31, 2023. doi:10.1001/jamapsychiatry.2023.1321 Debras C, Chazelas E, Sellem L, Porcher R, Druesne-Pecollo N, Esseddik Y et al. Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Santé cohort BMJ 2022; 378 :e071204 doi:10.1136/bmj-2022-071204 Nikolova VL, Cleare AJ, Young AH, Stone JM. Acceptability, Tolerability, and Estimates of Putative Treatment Effects of Probiotics as Adjunctive Treatment in Patients With Depression: A Randomized Clinical Trial. JAMA Psychiatry. Published online June 14, 2023. doi:10.1001/jamapsychiatry.2023.1817

Episode 89: Alix Turoff MS, RD, CDN, CPT | Let's talk about Ozempic Show Notes: On this episode of the Alix Turoff Nutrition podcast, Alix is back with a new season! She starts the season off with a bang by talking about the medication that's on everyone's mind… Ozempic. She also discussed Mounjaro (tirzepatide). She's talking about everything from how these medications work, who they might be appropriate for, and the social media storm surrounding them. Research: Semaglutide for the treatment of obesity Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients with Type 2 Diabetes: The PIONEER 8 Trial Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Safety of Semaglutide Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5 Semaglutide for the treatment of overweight and obesity: A review Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5 Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review The Health at Every Size Paradigm and Obesity: Missing Empirical Evidence May Help Push the Reframing Obesity Debate Forward   Resources: Submit your questions for upcoming podcast episodes Get the 5 week Flexible Nutrition Starter Kit Apply for Alix's 12 week small group coaching program Apply for Alix's 1:1 coaching program Follow Alix on Instagram  Join Alix's private Facebook group Download your FREE Happy Hour Survival Guide Buy Alix's book on Amazon Shop my favorite products on Amazon Contact Alix via email   Be sure you're subscribed to this podcast to automatically receive your episodes!!!  If you enjoyed today's episode, I'd love it if you would take a minute to leave a rating and review! Subscribe to The Alix Turoff Nutrition Podcast Discount Codes: Built Bar: Use the code ALIX for 10% off your order Legion Athletics: Use the code Alix for 20% off your order